Catatonic Episodes Related to Substance Use: A Cross-Sectional Study Using Electronic Healthcare Records

References

• Bush, G., Fink, M., Petrides, G., Dowling, F., & Francis, A. (1996). Catatonia. I. Rating scale and standardized examination. Acta Psychiatrica Scandinavica, 93(2), 129–136. https://doi.org/https://doi.org/10.1111/j.1600-0447.1996.tb09814.x
   PubMed Web of Science ®Google Scholar
• Carroll, B. T. (2000). The universal field hypothesis of catatonia and neuroleptic malignant syndrome. CNS Spectrums, 5(7), 26–33. https://doi.org/https://doi.org/10.1017/s1092852900013365
   PubMedGoogle Scholar
• Carroll, B. T., Anfinson, T. J., Kennedy, J. C., Yendrek, R., Boutros, M., & Bilon, A. (1994). Catatonic disorder due to general medical conditions. In Journal of Neuropsychiatry and Clinical Neurosciences, 6(2), 122–133. https://doi.org/https://doi.org/10.1176/jnp.6.2.122
   PubMed Web of Science ®Google Scholar
• Caudron, M., Rolland, B., Deheul, S., Geoffroy, P. A., Thomas, P., & Amad, A. (2016). Catatonia and cannabis withdrawal: A case report. Substance Abuse, 37(1), 188–189. https://doi.org/https://doi.org/10.1080/08897077.2015.1052869
   PubMed Web of Science ®Google Scholar
• Chern, C. H., & Tsai, W. J. (1993). Acute amphetamine intoxication with catatonia: A case report. Zhonghua Yi Xue Za Zhi [Chinese Medical Journal]; Free China Ed, 51(4), 322–327.
   PubMedGoogle Scholar
• Cuevas-Esteban, J., Iglesias‐González, M., Serra‐Mestres, J., Butjosa, A., Canal‐Rivero, M., Serrano‐Blanco, A., & Baladon, L. (2020). Catatonia in elderly psychiatric inpatients is not always associated with intense anxiety: Factor analysis and correlation with psychopathology. International Journal of Geriatric Psychiatry, 35(11), 1409–1417. https://doi.org/https://doi.org/10.1002/gps.5382
   PubMed Web of Science ®Google Scholar
• D'Souza, D. C., Perry, E., MacDougall, L., Ammerman, Y., Cooper, T., Wu, Y.-T., Braley, G., Gueorguieva, R., & Krystal, J. H. (2004). The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology, 29(8), 1558–1572. https://doi.org/https://doi.org/10.1038/sj.npp.1300496
   PubMed Web of Science ®Google Scholar
• Daniels, J. (2009). Catatonia: Clinical aspects and neurobiological correlates. The Journal of Neuropsychiatry and Clinical Neurosciences, 21(4), 371–380. https://doi.org/https://doi.org/10.1176/jnp.2009.21.4.371
   PubMed Web of Science ®Google Scholar
• Di Forti, M., Marconi, A., Carra, E., Fraietta, S., Trotta, A., Bonomo, M., Bianconi, F., Gardner-Sood, P., O'Connor, J., Russo, M., Stilo, S. A., Marques, T. R., Mondelli, V., Dazzan, P., Pariante, C., David, A. S., Gaughran, F., Atakan, Z., Iyegbe, C., … Murray, R. M. (2015). Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: A case-control study. The Lancet. Psychiatry, 2(3), 233–238. https://doi.org/https://doi.org/10.1016/S2215-0366(14)00117-5
   PubMed Web of Science ®Google Scholar
• Edward, S., & Fink, M. (2018). The madness of fear: A history of catatonia. Oxford University Press.
   Google Scholar
• Fleckenstein, A. E., Volz, T. J., Riddle, E. L., Gibb, J. W., & Hanson, G. R. (2007). New insights into the mechanism of action of amphetamines. Annual Review of Pharmacology and Toxicology, 47, 681–698. https://doi.org/https://doi.org/10.1146/annurev.pharmtox.47.120505.105140
   PubMed Web of Science ®Google Scholar
• Fearon, P., Kirkbride, J. B., Morgan, C., Dazzan, P., Morgan, K., Lloyd, T., Hutchinson, G., Tarrant, J., Fung, W. L. A., Holloway, J., Mallett, R., Harrison, G., Leff, J., Jones, P. B., & Murray, R. M. (2006). Incidence of schizophrenia and other psychoses in ethnic minority groups: Results from the MRC AESOP Study. Psychological Medicine, 36(11), 1541–1550. https://doi.org/https://doi.org/10.1017/S0033291706008774
   PubMed Web of Science ®Google Scholar
• FRANK. (2021). Honest information about drugs. www.talktofrank.com. https://www.gov.uk/government/organisations/home-office/series/drug-misuse-declared
   Google Scholar
• Home Office. (2017). Drug misuse: Findings from the 2015/16 Crime Survey for England and Wales. https://www.gov.uk/government/organisations/home-office/series/drug-misuse-declared
   Google Scholar
• Jonkman, S., & Kenny, P. J. (2013). Molecular, cellular, and structural mechanisms of cocaine addiction: A key role for microRNAs. Neuropsychopharmacology, 38(1), 198–211. https://doi.org/https://doi.org/10.1038/npp.2012.120
   PubMed Web of Science ®Google Scholar
• Lander, M., Bastiampillai, T., & Sareen, J. (2018). Review of withdrawal catatonia: What does this reveal about clozapine? Translational Psychiatry, 8(1), 139–154. https://doi.org/https://doi.org/10.1038/s41398-018-0192-9
   PubMedGoogle Scholar
• Levinsohn, E. A., & Hill, K. P. (2020). Clinical uses of cannabis and cannabinoids in the United States. Journal of the Neurological Sciences, 411, 116717. https://doi.org/https://doi.org/10.1016/j.jns.2020.116717
   PubMed Web of Science ®Google Scholar
• Leweke, F. M., Piomelli, D., Pahlisch, F., Muhl, D., Gerth, C. W., Hoyer, C., Klosterkötter, J., Hellmich, M., & Koethe, D. (2012). Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Translational Psychiatry, 2, e94. https://doi.org/https://doi.org/10.1038/tp.2012.15
   PubMed Web of Science ®Google Scholar
• Lerner, A., & Klein, M. (2019). Dependence, withdrawal and rebound of CNS drugs: An update and regulatory considerations for new drugs development. Brain Communications, 1(1), fcz025. https://doi.org/https://doi.org/10.1093/braincomms/fcz025
   PubMedGoogle Scholar
• Liakoni, E., Dolder, P. C., Rentsch, K. M., & Liechti, M. E. (2016). Presentations due to acute toxicity of psychoactive substances in an urban emergency department in Switzerland: A case series. BMC Pharmacology and Toxicology, 17(1), 1–7. https://doi.org/https://doi.org/10.1186/s40360-016-0068-7
   PubMedGoogle Scholar
• McHugh, M. L. (2012). Interrater reliability: The kappa statistic. Biochemia Medica, 22(3), 276–282. https://doi.org/https://doi.org/10.11613/BM.2012.031
   PubMed Web of Science ®Google Scholar
• Moeller, K. E., Kissack, J. C., Atayee, R. S., & Lee, K. C. (2017). Clinical interpretation of urine drug tests: What clinicians need to know about urine drug screens. Mayo Clinic Proceedings, 92(5), 774–796. https://doi.org/https://doi.org/10.1016/j.mayocp.2016.12.007
   PubMed Web of Science ®Google Scholar
• Oduola, S., Das-Munshi, J., Bourque, F., Gayer-Anderson, C., Tsang, J., Murray, R. M., Craig, T. K. J., & Morgan, C. (2021). Change in Incidence rates for psychosis in different ethnic groups in south London: Findings from the Clinical Record Interactive Search-First Episode Psychosis (CRIS-FEP) study. Psychological Medicine, 51(2), 300–309. https://doi.org/https://doi.org/10.1017/S0033291719003234
   PubMed Web of Science ®Google Scholar
• Palma-Álvarez, R. F., Soriano-Dia, A., Ros-Cucurull, E., Daigre, C., Serrano-Pérez, P., Ortega-Hernández, G., Perea-Ortueta, M., Gurrea Salas, D., Ramos-Quiroga, J.-A., & Grau-López, L. (2021). Catatonia related to cannabis and synthetic cannabinoids: A review. Journal of Dual Diagnosis, 17(2), 159–171. https://doi.org/https://doi.org/10.1080/15504263.2021.1904163
   PubMed Web of Science ®Google Scholar
• Rogers, J. P., Pollak, T. A., Begum, N., Griffin, A., Carter, B., Pritchard, M., Broadbent, M., Kolliakou, A., Ke, J., Stewart, R., Patel, R., Bomford, A., Amad, A., Zandi, M. S., Lewis, G., Nicholson, T. R., & David, A. S. (2021). Catatonia: Demographic, clinical and laboratory associations. Psychological Medicine. https://doi.org/https://doi.org/10.1017/S0033291721004402
   Google Scholar
• Sibanda, N. C., Kornhaber, R., Hunt, G. E., Morley, K., & Cleary, M. (2019). Prevalence and risk factors of emergency department presentations with methamphetamine intoxication or dependence: A systematic review and meta-analysis. Issues in Mental Health Nursing, 40(7), 567–578. https://doi.org/https://doi.org/10.1080/01612840.2018.1553003
   PubMed Web of Science ®Google Scholar
• Solmi, M., Pigato, G. G., Roiter, B., Guaglianone, A., Martini, L., Fornaro, M., Monaco, F., Carvalho, A. F., Stubbs, B., Veronese, N., & Correll, C. U. (2018). Prevalence of catatonia and its moderators in clinical samples: Results from a meta-analysis and meta-regression analysis. Schizophrenia Bulletin, 44(5), 1133–1150. https://doi.org/https://doi.org/10.1093/schbul/sbx157
   PubMed Web of Science ®Google Scholar
• Stewart, R., Soremekun, M., Perera, G., Broadbent, M., Callard, F., Denis, M., Hotopf, M., Thornicroft, G., & Lovestone, S. (2009). The South London and Maudsley NHS Foundation Trust Biomedical Research Centre (SLAM BRC) case register: Development and descriptive data. BMC Psychiatry, 9, 51. https://doi.org/https://doi.org/10.1186/1471-244X-9-51
   PubMed Web of Science ®Google Scholar
• Tait, R. J., Caldicott, D., Mountain, D., Hill, S. L., & Lenton, S. (2016). A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment. Clinical Toxicology, 54(1), 1–13. https://doi.org/https://doi.org/10.3109/15563650.2015.1110590
   PubMed Web of Science ®Google Scholar
• Walther, S., Stegmayer, K., Wilson, J. E., & Heckers, S. (2019). Structure and neural mechanisms of catatonia. The Lancet. Psychiatry, 6(7), 610–619. https://doi.org/https://doi.org/10.1016/S2215-0366(18)30474-7
   PubMed Web of Science ®Google Scholar
• Wojtowicz, J. M., Yarema, M. C., & Wax, P. M. (2008). Withdrawal from gamma-hydroxybutyrate, 1,4-butanediol and gamma-butyrolactone: A case report and systematic review. CJEM, 10(1), 69–74. https://doi.org/https://doi.org/10.1017/s1481803500010034
   PubMedGoogle Scholar